Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Japan Exchange
06/14/2021 06/15/2021 06/16/2021 06/17/2021 06/18/2021 Date
1911.5 1944.5 1951.5 1939.5 1943 Last
3812300 4185800 3399900 3027200 6237000 Volume
-0.88% +1.73% +0.36% -0.61% +0.18% Change
Financials
Sales 2021 1 259 B 11 440 M 11 440 M
Net income 2021 176 B 1 603 M 1 603 M
Net cash position 2021 522 B 4 740 M 4 740 M
P/E ratio 2021 20,1x
Yield 2021 2,16%
Sales 2022 1 326 B 12 047 M 12 047 M
Net income 2022 211 B 1 914 M 1 914 M
Net cash position 2022 430 B 3 908 M 3 908 M
P/E ratio 2022 17,0x
Yield 2022 2,52%
Capitalization 3 609 B 32 733 M 32 799 M
EV / Sales 2021 2,45x
EV / Sales 2022 2,40x
Nbr of Employees 15 883
Free-Float 99,0%
More Financials
Company
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others. 
Sector
Pharmaceuticals
Calendar
07/23Earnings Release
More about the company
Ratings of Astellas Pharma Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A-
More Ratings
All news about ASTELLAS PHARMA INC.
06/17ASTELLAS PHARMA  : Notice Regarding Impairment Loss Following the Termination of..
PU
06/16ASTELLAS PHARMA  : Transfers Five Legacy Products in Europe, Russia, CIS and Asi..
PU
06/09ASTELLAS PHARMA  : New Research Reflects Astellas' Commitment to Acute Myeloid L..
AQ
06/08Heavyweights pull Nikkei lower, Topix gains on drugmakers' boost
RE
06/07Nikkei falls as market heavyweights offset gains in drugmakers
RE
06/02ASTELLAS PHARMA  : Reviewing capabilities for sustainable growth - Astellas Will..
PU
06/02PRESS RELEASE : MorphoSys to Acquire Constellation -2-
DJ
05/31Japanese shares end lower on profit-booking, drugmakers limit losses
RE
05/30Japanese shares retreat from 3-week high; drugmakers limit losses
RE
05/26Japanese shares fall on profit-taking, pandemic worries
RE
05/20ASTELLAS PHARMA  : and Seagen Announce Updated Results from Two Trials of PADCEV..
AQ
05/19ASTELLAS PHARMA  : Seagen and Astellas Announce Updated Results from Two Trials ..
BU
05/18Astellas to Present Data from Expanding Oncology Portfolio During the 2021 AS..
AQ
05/12ASTELLAS PHARMA  : Notice Regarding Continuation of the Performance-linked Stock..
PU
05/11PRESS RELEASE : AMSilk raises EUR 29M to accelerate commercialization of its hig..
DJ
More news
News in other languages on ASTELLAS PHARMA INC.
06/02Morphosys schluckt US-Krebsspezialisten - Aktie bricht ein
06/02ADOCIA  : trois nominations et une démission au conseil
06/02DGAP-NEWS : MorphoSys übernimmt Constellation -2-
06/02DGAP-ADHOC : MorphoSys AG übernimmt Constellation -2-
05/31TOKYO STOCK EXCHANGE : Borsa Tokyo chiude in ribasso su prese di profitto, bene ..
More news
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Average target price 2 455,38 JPY
Last Close Price 1 943,00 JPY
Spread / Highest target 85,3%
Spread / Average Target 26,4%
Spread / Lowest Target -15,1%
EPS Revisions
Managers and Directors
NameTitle
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Mamoru Sekiyama Independent Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC.21.89%32 733
JOHNSON & JOHNSON2.92%426 557
ROCHE HOLDING AG12.70%325 803
PFIZER, INC.5.43%217 246
NOVARTIS AG2.47%208 642
ABBVIE INC.5.57%199 795